Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Amylyx Pharmaceuticals, Inc. (AMLX : NSDQ)
 
 • Company Description   
Amylyx Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. It focuses on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals Inc. is based in CAMBRIDGE, Mass.

Number of Employees: 123

 
 • Price / Volume Information   
Yesterday's Closing Price: $12.08 Daily Weekly Monthly
20 Day Moving Average: 1,456,371 shares
Shares Outstanding: 109.82 (millions)
Market Capitalization: $1,326.62 (millions)
Beta: -0.31
52 Week High: $16.96
52 Week Low: $2.60
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -16.63% -16.49%
12 Week -16.52% -17.86%
Year To Date 0.00% 0.00%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
43 Thorndike St.
-
Cambridge,MA 02141
USA
ph: 617-682-0917
fax: -
investors@amylyx.com http://www.amylyx.com
 
 • General Corporate Information   
Officers
Joshua B. Cohen - Co-Chief Executive Officer
James M. Frates - Chief Financial Officer
Paul Fonteyne - Director
Daphne Quimi - Director
Karen Firestone - Director

Peer Information
Amylyx Pharmaceuticals, Inc. (GSAC)
Amylyx Pharmaceuticals, Inc. (CASI)
Amylyx Pharmaceuticals, Inc. (ALCD.)
Amylyx Pharmaceuticals, Inc. (OMNN)
Amylyx Pharmaceuticals, Inc. (CGPI.)
Amylyx Pharmaceuticals, Inc. (CATX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 03237H101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 03/03/26
Share - Related Items
Shares Outstanding: 109.82
Most Recent Split Date: (:1)
Beta: -0.31
Market Capitalization: $1,326.62 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.40 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.22 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 65.00% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 03/03/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.00
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 30.19%
vs. Previous Quarter: 19.57%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
12/31/25 - -
09/30/25 - -68.95
06/30/25 - -82.48
ROA
12/31/25 - -
09/30/25 - -61.52
06/30/25 - -70.15
Current Ratio
12/31/25 - -
09/30/25 - 13.70
06/30/25 - 8.72
Quick Ratio
12/31/25 - -
09/30/25 - 13.70
06/30/25 - 8.72
Operating Margin
12/31/25 - -
09/30/25 - -
06/30/25 - -
Net Margin
12/31/25 - -
09/30/25 - -
06/30/25 - -
Pre-Tax Margin
12/31/25 - -
09/30/25 - -
06/30/25 - -
Book Value
12/31/25 - -
09/30/25 - 3.02
06/30/25 - 1.88
Inventory Turnover
12/31/25 - -
09/30/25 - -
06/30/25 - -
Debt-to-Equity
12/31/25 - -
09/30/25 - 0.00
06/30/25 - 0.00
Debt-to-Capital
12/31/25 - -
09/30/25 - 0.00
06/30/25 - 0.00
 

Powered by Zacks Investment Research ©